We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+31.91%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$158M
AUM Growth
+$48.6M
Cap. Flow
+$17.3M
Cap. Flow %
10.96%
Top 10 Hldgs %
69.15%
Holding
41
New
16
Increased
13
Reduced
5
Closed
3

Top Buys

1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.03M
2
RPRX icon
Royalty Pharma
RPRX
+$5.87M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$5.12M
4
ZVRA icon
Zevra Therapeutics
ZVRA
+$4.75M
5
URGN icon
UroGen Pharma
URGN
+$4.16M

Top Sells

1
ALIM
Alimera Sciences
ALIM
+$19.5M
2
RVNC
Revance Therapeutics, Inc.
RVNC
+$9.84M
3
EOLS icon
Evolus
EOLS
+$4.02M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$1.71M
5
XOMA
Xoma
XOMA
+$1.49M

Sector Composition

1 Healthcare 99.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMA icon
1
ADMA Biologics
ADMA
$2.02B
$37.4M 23.62%
1,870,000
– –
EOLS icon
2
Evolus
EOLS
$377M
$22.2M 14.02%
1,369,821
-287,790
-17% -$4.02M
LKFT
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$13.8M 8.71%
478,659
-6,341
-1% -$173K
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$15.5B
$6.13M 3.87%
+55,000
New +$6.03M
RPRX icon
5
Royalty Pharma
RPRX
$25.8B
$6M 3.79%
+212,000
New +$5.87M
XOMA
6
DELISTED
Xoma
XOMA
$5.17M 3.26%
195,096
-55,033
-22% -$1.49M
RIGL icon
7
Rigel Pharmaceuticals
RIGL
$750M
$5M 3.16%
309,100
+4,100
+1% +$48.2K
ZVRA icon
8
Zevra Therapeutics
ZVRA
$755M
$4.86M 3.07%
+700,000
New +$4.75M
ANIK icon
9
Anika Therapeutics
ANIK
$203M
$4.68M 2.95%
189,308
+23,911
+14% +$620K
RVNC
10
DELISTED
Revance Therapeutics, Inc.
RVNC
$4.26M 2.69%
820,000
-1,980,000
-71% -$9.84M
IRWD icon
11
Ironwood Pharmaceuticals
IRWD
$635M
$4.12M 2.6%
1,000,000
+951,988
+1,983% +$5.12M
VSTM icon
12
Verastem
VSTM
$530M
$3.92M 2.48%
+1,310,287
New +$3.56M
OPTN
13
DELISTED
OptiNose
OPTN
$3.81M 2.41%
379,239
+222,572
+142% +$3.25M
URGN icon
14
UroGen Pharma
URGN
$1.96B
$3.56M 2.25%
+280,345
New +$4.16M
SCPH
15
DELISTED
scPharmaceuticals
SCPH
$3.55M 2.24%
778,874
+357,171
+85% +$1.73M
ESTA icon
16
Establishment Labs
ESTA
$2.72B
$3.25M 2.05%
+75,000
New +$3.26M
ACAD icon
17
Acadia Pharmaceuticals
ACAD
$4.38B
$3.03M 1.91%
196,895
+191,895
+3,838% +$3.2M
DAWN
18
DELISTED
Day One Biopharmaceuticals
DAWN
$2.87M 1.81%
+205,675
New +$2.93M
ACRS icon
19
Aclaris Therapeutics
ACRS
$793M
$2.83M 1.79%
2,458,873
+531,427
+28% +$652K
TELA icon
20
TELA Bio
TELA
$32.7M
$2.81M 1.77%
1,110,000
+484,355
+77% +$1.72M
INDV icon
21
Indivior Pharmaceuticals
INDV
$4.79B
$2.63M 1.66%
+270,000
New +$3.16M
XGN icon
22
Exagen
XGN
$106M
$1.65M 1.04%
534,398
+175,701
+49% +$455K
MIST icon
23
Milestone Pharmaceuticals
MIST
$148M
$1.52M 0.96%
999,790
-239,409
-19% -$348K
SRZN icon
24
Surrozen
SRZN
$255M
$1.32M 0.83%
110,000
+43,916
+66% +$388K
AYTU icon
25
AYTU BioPharma
AYTU
$23.1M
$1.18M 0.74%
500,958
+28,489
+6% +$73.8K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Stonepine Capital Management held 41 positions worth $158M, up 44% from $110M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Stonepine Capital Management deployed $17.3M of net new capital in Q3 2024, opening 16 new positions and adding to 13 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 55,000 shares worth $6.13M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Revance Therapeutics, Inc., an estimated $9.84M trimmed.

  • Stonepine Capital Management's largest Q3 2024 buy was Jazz Pharmaceuticals: 55,000 shares worth $6.13M.
  • Stonepine Capital Management added most to Ironwood Pharmaceuticals in Q3 2024, an estimated $5.12M increase.
  • Stonepine Capital Management's biggest Q3 2024 reduction was Revance Therapeutics, Inc., cutting an estimated $9.84M.
  • Stonepine Capital Management fully exited Alimera Sciences in Q3 2024, selling an estimated $19.5M.
  • Stonepine Capital Management's ten largest holdings make up 69% of its $158M portfolio in Q3 2024.
  • Stonepine Capital Management opened 16 new positions and closed 3 in Q3 2024.
  • Stonepine Capital Management's portfolio value rose 44% quarter-over-quarter to $158M.

Based on Stonepine Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.